Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025

LONDON, August 26, 2015 /PRNewswire/ --

Pharma Sales in China - How to Assess Trends and Potential Revenues, Benefiting Your Influence 

What does the future hold for China's pharma market? Can it sustain high growth? Visiongain's new report gives you forecasted revenues there to 2025. Our work explains medical and technological trends, prospects and commercial opportunities.

China retains great potential for sales of prescription drugs and OTC medicines. Our updated study gives data and multilevel revenue predictions. There you investigate activities of domestic and international companies, assessing prospects for their expanding market.

Our analysis shows you the most lucrative parts of Chinese pharmaceutical sales. Read on, then, to explore that market and see what revenue it could achieve in future.

Forecasts and other analyses to help you stay ahead on China's pharma market 

Our new survey shows you revenue predictions to 2025, historical data, growth rates and market shares. It explores business outlooks, trends and leading companies. With that work you gain 76 tables, 82 charts and two interviews with organisations.

Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses, plans, decisions and authority. The following sections explain how our investigation helps your work.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Sales predictions for the Chinese drug market and its segments - discover sales potentials 

Along with revenue prediction for the overall Chinese pharma market, our study shows individual forecasting to 2025 for these therapeutic submarkets:
• Infectious diseases - antibiotics and other anti-infective products
• Cancer - applications in oncology, anticancer agents
• Cardiovascular disorders - with sub-forecasts for hypertension and dyslipidaemia
• Diabetes therapies    

• Respiratory diseases - with sub-forecasts for COPD and asthma treatments
• Autoimmune conditions
• Central nervous system (CNS) disorders - with sub-forecasting for antidepressants
• Other medical needs (grouped).

Our report also gives individual revenue forecasts to 2025 by product class and sales channel:
• Small-molecule pharmaceuticals - with sub forecasts for original-branded medicines prescription drugs and generics
• Biological drugs - with sub forecasts for novel biologics, biosimilars and vaccines
• Traditional Chinese medicines (TCM)
• Hospitals
• Retail pharmacies
• Clinics and other channels
• Over-the-counter (OTC) products.

China remains an exciting and important market for pharmaceutical companies. Our study shows you what is possible there from 2015, including high demand for treatments.

For prominent diseases in China, our survey lets you assess prevalence and incidence rates to 2025. Discover treatment opportunities for pharmaceutical companies from 2015.

With our analysis you explore what influences Chinese healthcare industries and markets.

Trends, characteristics and other forces shaping the Chinese pharma market 

Our report discusses issues, regulations and other events influencing Chinese healthcare and related industries from 2015:
• Epidemiological trends - explore treatment needs underpinning Chinese healthcare
• Institutions regulating the pharmaceutical industry - policy generation
• Chinese healthcare reform - initiatives, e.g. Healthy China 2020, affecting drug producers and marketers
• Opportunities in treating chronic diseases, including HIV and hepatitis
• Protection of intellectual property - progress and challenges
• Sales outlets - distribution channels most important from 2015 to 2025.

Our study also discusses other aspects of medical businesses in China, including these developments:
• Manufacturing and R&D, including biotechnology and trends for venture capital
• Healthcare funding - driving and restraining forces
• Discussion of the Anhui model and its implications
• Investment in rural healthcare - high demands needing served, giving opportunities
• Branded generics - their prospects for expanding treatment coverage
• Biosimilar drug manufacturers - harnessing China's strengths in biopharma.

With our investigation you explore technological, economic, social and political trends. You also analyse that market's strengths, weaknesses, opportunities and threats. Discover, from 2015 to 2025, what the future holds for pharma companies operating in China.

Leading companies - domestic and foreign - and overall 2019 market value
What happens next? Our report predicts overall pharma sales in China will reach $227bn in 2019, expanding onwards to 2025. Explore what is possible in that vast, fast-growing market.

Our study covers these multinational companies and other foreign organisations developing that market:
• AbbVie
• Eli Lilly
• GlaxoSmithKline
• AstraZeneca
• Johnson & Johnson
• Novo Nordisk
• Novartis
• Bayer
• Pfizer
• Roche
• Merck & Co.

Our survey also discusses leading Chinese pharma companies, with ranking of the top 50 by revenue. See the roles they serve and their outlooks for the future. These and many other domestic firms appear in the study:
• Guangzhou Pharmaceutical Holdings
• Shanghai Pharmaceuticals
• Yunnan Baiyao
• Harbin Pharmaceuticals
• Xiuzheng Pharmaceutical Group
• Sinopharm.

In our report you also discover interviews with other authorities on Chinese pharma, helping you stay ahead for commercial insight.

From 2015 there will arise many opportunities in China for drug companies to develop their businesses. Our work shows you the medical, technological and commercial possibilities. Assess what is possible in Chinese healthcare to 2025.

Ways Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 helps you 

In these main ways, our investigation benefits your research, analysis and plans, helping you stay ahead:
• Pharma revenues in China to 2025 at overall national level and for 26 submarkets - assess outlooks for investments, production, marketing and sales
• Epidemiological trends - see treatment needs by disease, assessing data on present and future healthcare demands
• Prospects for established competitors, rising companies and new entrants - explore results, R&D, technologies, strategies and outlooks for success
• Interviews with authorities on Chinese pharma - assess opinions and other qualitative analyses to help you compete and succeed.

That report, by visiongain's in-house UK-based analysts, gives knowledge to benefit your research, analyses, decisions and proposals. Get data leading companies depend on.

Information there found nowhere else, benefiting your knowledge and influence 

Our study gives independent analysis. There you receive predictions found only in our work, seeing where technological and financial prospects are most rewarding.

With our investigation you are less likely to fall behind in knowledge or miss opportunity. See there how you could help your research, planning and presentations, also saving time and benefiting your reputation for commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing the vast Chinese market. Find its growth potential and see how you could gain.

Trying our report now lets you discover where the money lies in Chinese pharma 

Our new study is for everyone analysing Chinese healthcare. There you find data, trends, opportunities and sales predictions. Avoid falling behind - get our new report here now

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100

Or click on https://goo.gl/L2NeDd

Organisations Mentioned in the Report
3SBio
Acambis
Agilent
Alibaba Group
Alliance Boots
Amerisource-Bergen
Amgen
Anhui Anke Biotech
AppTech Laboratory Services
Asian Cancer Research Group
Astellas
AstraZeneca
Asymchem Laboratories
AXM Pharma
Baxter
Bayer
Bayer Healthcare
BeiGene
Beijing Four Rings Bio-pharmaceutical
Beijing Genomics Institute
Beijing Kexing Bioproducts
Beijing Key Yuan Xinhai Pharmaceutical
Beijing SL Pharmaceutical
Beijing Taiyang
Beijing Tiantan Biological Products
Beijing Tong Ren Tang
Bio-Bridge Science
BiODura
Bloomberg
Boehringer Ingelheim
Bristol-Myers Squibb
Buchang Pharma
Cardinal Health
CASiGEN Pharma
Celgene
Celsion Corp
Changzhou Qianhong Biopharma
Chemizon (Beijing) Pharma-Tech
Chengdu Di'ao Pharmaceutical Group
Chengdu Institutes of Biological Products
Chiesi Edding Hong Kong Limited
Chi-Med
China Chemical & Pharmaceutical Group
China Food and Drug Administration (CFDA)
China National Accord

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

China National Biotec Group
China National Pharmaceutical Group
China NT Pharma Group
China Pharmaceutical Commerce Association
China Pharmaceutical Quality Management Association
China Resources Double-Crane Pharmaceuticals
China Resources Sanjiu Medical
China Shineway Pharmaceutical
China Traditional Chinese Medicine Co.
ChinaBio Group
ChinaGate
China Academy of Chinese Medical Sciences
Chinese Academy of Sciences (CAS)
Chinese Center for Drug Evaluation
Chinese Ministry of Commerce
Chonqqing Taiji Industry
Cipla
Consun Pharmaceutical Group
Cord Blood America
Covance
CSPC Pharmaceutical Group
Daan Gene
Daiichi Sankyo
Dalian Hissen Bio-Pharm
Dawnrays Pharmaceutical Holdings
Diabetes Society
Dihon Pharmaceutical Group
Dongsheng Pharmaceutical
Dr. Reddy's Laboratories
Egret
Eisai
Eli Lilly
Excel PharmaStudies
FeRx Incorporated
Financial Times
Foshan City
Furen Pharmaceutical Group
Gan & Lee Pharmaceutical
Genentech
GeneScience Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
Goldman Sachs
Guangdong BeiKang Pharmaceutical
Guangdong Techpool
Guangxi Wuzhou Zhongheng Group
Guangzhou Medical University
Guangzhou Pharma
Guangzhou Pharmaceutical Corporation
Guizhou Baiqiang Pharmaceutical
Hangzhou East China Pharmaceutical Group
Hangzhou Jiuyuan Gene Engineering
Hangzhou Tigermed Consulting
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
Harbin Tri-Lion Pharmaceutical
Harvard University
HD Biosciences
Henan Lingrui Pharmaceutical
Hengrui
Henlius Biopharmaceuticals
HitGen
Hua Medicine
Huadong Medicine
Hualan Biological Engineering
Hualida Biotech
Hutchinson Whampoa
Hutchison MediPharma
i3 Research
ICON
Inner Mongolia Yili Energy
Innovent Biologics
JD.com (Jindong Mall)
JHL Biotech
Jiangsu Chia-tai Tianqing Pharmaceutical
Jiangsu Hansen Pharmaceutical
Jiangsu Hansoh Pharmaceutical
Jiangsu Hengrui Medicine
Jiangsu Nhwa Pharmaceutical
Jilin Extrawell Changbaishan
Jilin Province Huinan Changlong
Jinling Pharmaceutical
Johnson & Johnson
Joincare Pharma
JOINN Laboratories
Kangmei Pharmaceutical
KPC Pharmaceuticals
Lepu Medical
Livzon Pharmaceutical Group
Lundbeck
Lundbeck Institute
Massachusetts Institute of Technology
McKesson
Merck & Co.
Merck Sharp & Dohme
Microport Medical
Ministry of Commerce of the People's Republic of China
Ministry of Health of the People's Republic of China
Ministry of Labor and Social Security of the People's Republic of China
Mycenax
Mylan
Nanjing Kanghai Pharmaceutical
Nanjing Pharmaceutical Factory
National Development and Reform Commission
National Institute for the Control of Pharmaceutical and Biological Products
Nestle Health Sciences
Nestle SA
Newsummit Biopharma
North China Pharmaceutical Group
Northeast Pharmaceutical Group (NEPG)
Northwest University
Novartis
Novast Laboratories
Novo Nordisk
Oncobiologics
Otsuka
Pfizer
Pharmaceutical Product Development LLC
Pharmaron
PKU Healthcare Group
Qilu Pharmaceutical
Quintiles
Roche
Sanofi
Schering-Plough
Servier
Shandong Dong-E E-Jiao
Shandong Kexing Bioproducts
Shandong University
Shanghai Celgen Bio-Pharmaceutical
Shanghai Charity Foundation
Shanghai CP Guojian Pharmaceuticals
Shanghai DND Pharm-Technology
Shanghai Fosun Pharmaceutical Group
Shanghai Furen Industrial
Shanghai Institutes of Biological Sciences
Shanghai Jinhe Bio-Technology
Shanghai Pharmaceuticals Holding
ShangPharma
Shenzhen Heapalink
Shenzhen Kangtai Biological Products
Shenzhen Neptunus Bioengineering
Shenzhen Salubris Pharmaceuticals
Shenzhen Wenle ('Main Luck') Pharmaceutical
Shijiazhuang Pharmaceutical Group
Shijiazhuang Yiling
Shineway Pharmaceutical Group
Sichuan Jiufeng Pharmaceutical
Sichuan Kelun Pharmaceutical
Sichuan Kelun Pharmaceutical
Sichuan Yuanda Shuyang Pharmaceutical
Sihuan Pharmaceutical Holdings
Simcere Pharmaceutical
SiniWest Holdings
Sino Biological
Sino Biopharmaceutical
Sinopharm
State Key Lab of Respiratory Disease
State Traditional Chinese Medicine Administration
Sundia MediTech
Sundiro Pharma
Swiss Re
Symbio Pharmaceuticals
Takeda
Tangshan Yian Bioengineering
Tasly Pharmaceuticals
Teva
The World Bank
The Financial Times
Thermo Fisher Scientific
Tianjin Jin Yao Group
Tianjin Kinnovata Pharmaceutical Company
Tonghua Dongbao
United Pharmatech
University of Warwick
US Food and Drug Administration
Vectura
Venturepharm Laboratories
Vertex Pharmaceuticals
Viva Biotech
Wai Yuen Tong Medicine Holdings
Walmart Holdings
Wanbang Biopharmaceuticals
Washington University
Weigao Holding
Winteam Pharmaceutical Group
WHO World Health Organization
WTO World Trade Organization
WuXi AppTec
Xiamen Amoytop Biotech
Xian-Janssen Pharmaceuticals
Xiuzheng Pharmaceutical
Xizang Haisco
Yabao Pharmaceutical Group
Yangtze River Pharmaceuticals
Youcare Pharmaceutical Group
Yunnan Baiyao
Zai Lab
Zendex Bio Strategy
Zensun (Shanghai) Sci & Tech
Zhejiang Beta Pharma
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Medicine
Zhejiang Tianyuan
Zhenjian Hisun Pharmaceuticals
Zhuhai United States Labs
Zuellig Pharma China

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100

Or click on https://goo.gl/L2NeDd